Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine

Journal of Microbiological Methods

Volumn 82, Issue 3, 2010, Pages 334-337

  Talebkhan, Y ^a   Bababeik, M ^a   Esmaeili, M ^a   Oghalaei, A ^a   Saberi, S ^a   Karimi, Z ^a   Afkhami, N ^a   Mohammadi, M ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Cloning; Immunization; Therapeutic vaccine

Indexed keywords

ANTIBODY; CHOLERA TOXIN; HELICOBACTER PYLORI VACCINE; RECOMBINANT OMP18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; DNA SEQUENCE; ESCHERICHIA COLI; EXPERIMENTAL MOUSE; FEMALE; GRAM STAINING; HELICOBACTER INFECTION; HELICOBACTER PYLORI BACTERIAL GHOST; IMMUNOBLOTTING; INFECTION RATE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTICAL DENSITY; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; MUS;

EID: 77955658318     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2010.07.001     Document Type: Article

References (32)

1. Azimpour Tabrizi C., Walcher P., Mayr U., Stiedl T., Binder M., MacGrath J., Lubitz W. Bacterial ghosts-biological particles as delivery systems for antigens, nucleic acids and drugs. Cur. Opin. Biotechnol. 2004, 15:530-537.
2. Eko F., Mayr U., Attridge S., Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol. 2000, 83:115-123.
3. Eko F., He Q., Brown T., McMillan L., Ifere G.O., Ananaba G.A., Lyn D., Lubitz W., Kellar K.L., Black C.M., Igietseme J.U. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 2004, 173:3375-3382.
4. Filipec Kanizaj T., Katicic M., Presecki V., Gasparov S., Colić Cvrlje V., Kolarić B., Mrzljak A. Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases-cross-sectional study. Croat. Med. J. 2009, 50:124-132.
5. Fock K., Talley N., Moayyedi P., Hunt R., Azuma T., Sugano K., Xiao S., Lam S., Goh K., Chiba T., Uemura N., Kim J., Kim N., Ang T., Mahachai V., Mitchell H., Rani A., Liou J., Vilaichone R., Sollano J. Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J. Gastroenterol. Hepatol. 2008, 23:351-365.
6. Fock K., Katelaris P., Sugano K., Ang T., Hunt R., Talley N., Lam S., Xiao S., Tan H., Wu C., Jung H., Hoang B., Kachintorn U., Goh K., Chiba T., Rani A. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009, 24:1587-1600.
7. Hensel A., Huter V., Katinger A., Raza P., Strnistschie C., Roessler U., Brand E., Lubitz W. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 2000, 18:2945-2955.
8. Huter V., Hensel A., Brand E., Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 2000, 83:161-172.
9. IARC World Health Organization. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Helicobacter pylori. Schistosomes, Liver Flukes and Helicobacter pylori: Views and Expert Opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 1994, 177-240. World Health Organization, Lyon.
10. Javala K., Hensel A., Szostak M., Resch S., Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J. Control. Release 2002, 85:17-25.
11. Jechlinger W., Haller C., Resch S., Hofmann A., Szostak M.P., Lubitz W. Comparative immunogenicity of the Hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine 2005, 23:3609-3617.
12. Jiang Z., Tao X., Huang A., Wang P. A study of recombinant protective H. pylori antigens. World J. Gastroenterol. 2002, 8:308-311.
13. Kotloff K., Sztein M., Wasserman S., Losonsky G., DiLorenzo S., Walker R. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 2001, 69:3581-3590.
14. Kusters J., van Vliet A., Kuipers E. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 2006, 19:449-490.
15. Losonsky G., Kotloff K., Walker R. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LTR192G in H. pylori seronegative individuals. Vaccine 2003, 21:562-565.
16. Malfertheiner P., Schultze V., Rosenkranz B., Kaufmann S., Ulrichs T., Novicki D., Norelli F., Contorni M., Peppoloni S., Berti D., Tornese D., Ganju J., Palla E., Rappuoli R., Scharschmidt B., Del Giudice G. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008, 135:787-795.
17. Marchart J., Rehagen M., Dropmann G., Szostak M.P., Alldinger S., Lechleitner S., Schlapp T., Resch S., Lubitz W. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 2003, 21:1415-1422.
18. Mégraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004, 64:1893-1904.
19. Mera R., Fontham E., Bravo L., Piazuelo M., Camargo M., Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005, 54:1536-1540.
20. Panthel K., Jechlinger W., Matis A., Rohde M., Szostak M., Lubitz W., Haas R. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 2003, 71:109-116.
21. Paukner S., Kohl G., Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J. Control. Release 2004, 94:63-74.
22. Rathinavelu S., Kao J., Zavros Y., Merchant J. Helicobacter pylori outer membrane protein 18 (Hp1125) induces dendritic cell maturation and function. Helicobacter 2005, 10:424-432.
23. Ruggiero P., Peppoloni S., Rappuoli R., Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man?. Microbes Infect. 2003, 5:749-756.
24. Sijun H., Yong X. Helicobacter pylori vaccine: mucosal adjuvant and delivery systems. Indian J. Med. Res. 2009, 130:115-124.
25. Sugano K. Prevention of gastric cancer: urgent need to implement Helicobacter pylori eradication therapy as a primary preventive measure in Japan. J. Gastroenterol. 2007, 42:1-2.
26. Summerton N., Welch R., Bondoc L., Yang H., Pleune B., Ramachandran N., Harris A., Bland D., Jackson W., Park S., Clements J., Nabors G. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28:1404-1411.
27. Sutton P., Doidge C., Pinczower G., Wilson J., Harbour S., Swierczak A., Lee A. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol. Med. Microbiol. 2007, 50:213-219.
28. Szostak M., Hensel A., Eko F., Klein R., Auer T., Mader H., Haslberger A., Bunka S., Wanner G., Lubitz W. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 1996, 44:161-170.
29. Talebkhan, Y., Ebrahimzadeh, F., Esmaeili, M., Zamaninia, L., Nahvijou, A., Khedmat, H., Fereidooni, F., Mohagheghi, M., Mohammadi, M., 2010. Helicobacter pylori Omp18 and its application in serologic screening of infection. Cur. Microbiol. doi: 10.1007/s00284-010-9694-2.
30. Voland P., Weeks D., Vaira D., Prinz C., Sachs G. Specific identification of three low molecular weight membrane-associated antigens of Helicobacter pylori. Aliment. Pharmacol. Ther. 2002, 16:533-544.
31. Voland P., Hafsi N., Zeitner M., Laforsch S., Wagner H., Prinz C. Antigenic properties of HpaA and Omp18, two outer membrane proteins of Helicobacter pylori. Infect. Immun. 2003, 7:3837-3843.
32. Witte A., Wanner G., Blasi U., Halfmann G., Szostak M., Lubitz W. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol. 1990, 172:4109-4114.